Filing Details

Accession Number:
0001714899-24-000098
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-04-02 18:07:46
Reporting Period:
2024-04-01
Accepted Time:
2024-04-02 18:07:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1714899 Denali Therapeutics Inc. DNLI () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1666236 E. Steve Krognes C/O Denali Therapeutics Inc.
161 Oyster Point Blvd.
South San Francisco CA 94080
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-04-01 92,500 $20.50 47,341 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 850,000 Indirect See footnote
Footnotes
  1. The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted December 1, 2023.
  2. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $20.06 to $20.73 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. Includes 16,716 unvested RSUs.
  4. The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee.